Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, ...
Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...
On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...
Frozen nutritional shakes given to hospital patients and long-term care residents have been recalled after they were linked ...
An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their ...